About this trial
The aim of the Walk BEST study is to provide evidence that it is feasible to implement the technology assisted gait- focused walking program Walk-BEST™ in older adults with osteoporosis, and that this program is acceptable to this population.
Eligibility criteria
Qualifiers
men and women 70 years and older
able to walk independently with or without a walking aid
experienced a prior fracture after the age of 40, OR two falls in the past 12 months, OR who have a bone mineral density test (done as part of routine clinical evaluation) with a T-score < -2.5, OR on a Health Canada-approved anti-osteoporosis medication (oral or intravenous bisphosphonate, denosumab, teriparatide, or romozosumab) to reduce fracture risk or on a bisphosphonate drug holiday (planned treatment interruption)
Disqualifiers
fracture sustained in the past 12 months
unable to walk unsupervised because of active medical or neurocognitive reasons
unable to provide informed consent, or cannot communicate in English or French
Trial design
Treatments tested in this trial
- Device: Heel2Toe[TM] sensor
- Technology-assisted therapeutic walking program